Lung perfusion with protective solution relieves lung injury in corrections of Tetralogy of Fallot

Annals of Thoracic Surgery

Volumn 77, Issue 3, 2004, Pages 918-924

  Wei, Bo ^a   Liu, Yinglong ^a   Wang, Qiang ^a   Yu, Cuntao ^a   Long, Cun ^a   Chang, Yongnan ^a   Ruan, Yingmao ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

21

Indexed keywords

CRYOPROTECTIVE AGENT; ENDOTHELIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MALONALDEHYDE; PROTECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ARTERIAL OXYGEN TENSION; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CARDIOPULMONARY BYPASS; CELL VACUOLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FALLOT TETRALOGY; FEMALE; HEMODYNAMIC MONITORING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPEREMIA; INFANT; INTENSIVE CARE UNIT; LEUKOCYTE; LUNG ALVEOLUS OXYGEN TENSION; LUNG BIOPSY; LUNG EDEMA; LUNG FUNCTION; LUNG LAVAGE; LUNG PERFUSION; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION SWELLING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

EID: 1442349122     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2003.09.072     Document Type: Article

References (25)

1. Liu Y.L., Wang Q., Zhu X.D., et al. Pulmonary artery perfusion with protective solution reduces lung injury after cardiopulmonary bypass. Ann Thorac Surg. 69:2000;1402-1407.
2. Tennenberg S.D., Clardy C.W., Bailey W.W., et al. Complement activation and lung permeability during cardiopulmonary bypass. Ann Thorac Surg. 50:1990;597-601.
3. Millar AB, Armstrong L, van der Linden, et al. Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 1993;56:1499-502.
4. Steinberg J.B., Kapelanski D.P., Olson J.D., et al. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 106:1993;1008-1016.
5. Chai P.J., Williamson J.A., Lodge A.J., et al. Effects of ischemia on pulmonary dysfunction after cardiopulmonary bypass. Ann Thorac Surg. 67:1999;731-735.
6. Friedman M., Sellke F.W., Wang S.Y., et al. Parameters of pulmonary injury after total or partial cardiopulmonary bypass. Circulation. 90:(5 Pt 2):1994;II262-268.
7. Kuratani T., Matsuda H., Sawa Y., et al. Experimental study in a rabbit model of ischemia-reperfusion lung injury during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 103:1992;564-568.
8. Gu Y.J., Wang Y.S., Chiang B.Y., et al. Reduction of granulocyte- mediated lung injury in canine cardiopulmonary bypass by anisodaminse infusion. Thorac Cardiovasc Surg. 39:(3):1991;154-157.
9. Hill GE, Alonso A, Spurzem JR, et al. Aprotinin and methylprednisolone equally blunt CPB-induced inflammation in humans. J Thorac Cardiovasc Surg 1995;110:1658-62.
10. Allen S., Anastasiou N., Royston D., et al. Effect of aprotinin on vascular reactivity of coronary artery bypass grafts. J Thorac Cardiovasc Surg. 113:1997;319-326.
11. Carrier M., Khalil A., Tourigny A., Solymoss B.C., Pelletier L.C. Effect of L-arginine on metabolic recovery of the ischemic myocardium. Ann Thorac Surg. 61:1996;1651-1657.
12. Replogle R.L., Gazzaniga A.B., Gross R.E. Use of corticosteroids during cardiopulmonary bypass possible lysosome stabilization. Circulation. 33:(Suppl 4):1966;I86-92.
13. Gibbons G.H. Endothelial function as a determinant of vascular function and structure a new therapeutic target. Am J Cardiol. 79:(5A):1997;3-8.
14. Luscher T.F., Barton M. Biology of the endothelium. Clin Cardiol. 20:(11 Suppl 2):1997;II-3-10.
15. Dreyer W.J., Burns A.R., Phillips S.C., et al. Intercellular adhesion molecule-1 regulation in the canine lung after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 115:1998;689-698. ; discussion 698-9.
16. Blume E.D., Nelson D.P., Gauvreau K., et al. Soluble adhesion molecules in infants and children undergoing cardiopulmonary bypass. Circulation. 96:(Suppl 9):1997;II-352-357.
17. Boldt J., Osmer C., Linke L.C., et al. Circulating adhesion molecules in pediatric cardiac surgery. Anesth Analg. 81:(6):1995;1129-1135., comment 1123-4.
18. Galea J., Rebuck N., Finn A., et al. Expression of soluble endothelial adhesion molecules in clinical cardiopulmonary bypass. Perfusion. 13:(5):1998;314-321.
19. Boyle E.M. Jr, Verrier E.D., Spiess B.D., et al. Endothelial cell injury in cardiovascular surgery the procoagulant response. Ann Thorac Surg. 62:1996;1549-1557.
20. Boyle E.M. Jr, Pohlman T.H., Johnson M.C., et al. Endothelial cell injury in cardiovascular surgery the systemic inflammatory response. Ann Thorac Surg. 63:1997;277-284.
21. Verrier E.D., Morgan E.N. Endothelial response to cardiopulmonary bypass surgery. Ann Thorac Surg. 66:(Suppl 5):1998;S17-19. ; discussion S25-8.
22. Etingin O.R., Silverstein R.L., Hajjar D.P., et al. von Willebrand factor mediates platelet adhesion to virally infected endothelial cells. Proc Natl Acad Sci USA. 90:(11):1993;5153-5156.
23. Siemiatkowski A., Kloczko J., Galar M., et al. von Willebrand factor antigen as a prognostic marker in posttraumatic acute lung injury. Haemostasis. 30:(4):2000;189-195.
24. Komai H., Adatia I.T., Elliott M.J., et al. Increased plasma of endothelin-1 after cardiopulmonary bypass in patients pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg. 106:1993;473-478.
25. Helset E., Lindal S., Olsen R., et al. Endothelin-1 causes sequential trapping of platelets, and neutrophils in pulmonary microcirculation in rats. Am J Physiol. 271:(4 Pt 1):1996;L538-546.